Total trials
273
Active
98
Phase 3
35
Total enrollment
153,012
Pipeline matrix
Showing 40 of 50 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Propranolol | — | — | — | — | 3 | ||
| Alteplase | — | — | — | — | — | 3 | |
| Valproic Acid 500 MG | — | — | — | — | — | 1 | |
| Misoprostol | — | — | — | — | — | 1 | |
| Combined oral contraceptive | — | — | — | — | — | 1 | |
| Vaginal Ring | — | — | — | — | — | 1 | |
| Cilostazol 100 MG | — | — | — | — | — | 9 | |
| Ticagrelor 90 MG | — | — | — | — | — | 9 | |
| Clopidogrel | — | — | — | — | — | 7 | |
| Apixaban 5MG | — | — | — | — | — | 2 | |
| Rivaroxaban 20 MG Oral | — | — | — | — | — | 2 | |
| Dabigatran Etexilate 150mg | — | — | — | — | — | 2 | |
| Clopidogrel 75 Mg Oral | — | — | — | — | — | 2 | |
| Rosuvastatin 20mg | — | — | — | — | — | 2 | |
| Aspirin 75mg | — | — | — | — | — | 2 | |
| Aspirin 75 Mg Oral | — | — | — | — | — | 1 | |
| Acetyl-Leucine | — | — | — | — | — | 1 | |
| aspirin 100mg | — | — | — | — | — | 1 | |
| Clopidogrel 75mg | — | — | — | — | — | 1 | |
| Atorvastatin 40 Mg Oral | — | — | — | — | — | 1 | |
| Atorvastatin 40mg | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Letrozole 2.5Mg Tab | — | — | — | — | — | 1 | |
| Adductor Canal Block (ACB) Only | — | — | — | — | — | 1 | |
| Sildenafil 25 MG | — | — | — | — | — | 1 | |
| L-Arginine, 1000 Mg Oral | — | — | — | — | — | 1 | |
| Group C | — | — | — | — | — | 1 | |
| Demineralized Allogeneic Dentin Graft | — | — | — | — | — | 1 | |
| Mineralized Allogeneic Dentin Graft | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 | |
| Vastus lateralis nerve block | — | — | — | — | — | 1 | |
| Lateral femoral cutaneous nerve block | — | — | — | — | — | 1 | |
| Arm 2 Metformin Gel 1% | — | — | — | — | — | 1 | |
| Arm 3 Chlorhexidine Gel 0.2% | — | — | — | — | — | 1 | |
| After successful revacularization, We will categorize patients into two groups : groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the woun | — | — | — | — | — | 1 | |
| Silver Nanoparticles Irrigant | — | — | — | — | — | 1 | |
| Sacubitril/Valsartan | — | — | — | — | — | 1 | |
| Conventional anti-heart failure therapy | — | — | — | — | — | 1 | |
| Intracoronary tirofiban | — | — | — | — | — | 1 | |
| Saline 0.9% | — | — | — | — | — | 1 |
10 more active programs hidden
Next readouts
- 2024-07-01
- 2024-07-01
- 2024-09-01
- 2024-09-01
- 2024-09-10
- 2024-09-15
- 2024-09-15
- 2024-09-30
- 2024-12-20
- 2025-05-15
Top conditions
- Ischemic Stroke21
- Dexmedetomidine11
- Dental Implant Failed8
- Erector Spinae Plane Block6
- Migraine Disorders5
- COVID-195
- Analgesia5
- Ultrasound4
Frequently asked questions about Kafrelsheikh University
- How many clinical trials does Kafrelsheikh University have on ClinicalTrials.gov?
- Kafrelsheikh University is listed as the lead sponsor on 273 clinical trials in ClinicalTrials.gov, 98 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Kafrelsheikh University's trials are in Phase 3?
- 35 of Kafrelsheikh University's trials are in Phase 3, spread across 50 active drug programs.
- What therapeutic areas does Kafrelsheikh University focus on?
- Kafrelsheikh University's most-studied conditions on ClinicalTrials.gov are Ischemic Stroke, Dexmedetomidine, Dental Implant Failed, Erector Spinae Plane Block, Migraine Disorders.
- When are Kafrelsheikh University's next clinical trial readouts?
- Kafrelsheikh University has 10 upcoming primary-completion readouts tracked here; the soonest is “Valproate Versus Propranolol in Migraine”, expected around 2024-07-01.